Liquidia (LQDA) stock closed meaningfully lower on Thursday after United Therapeutics (UTHR) secured a major victory against the biopharmaceutical firm in a U.S. District Court. The Delaware court ruled that LQDA’s flagship pulmonary hypertension drug Yutrepia infringes on two valid claims of UHTR’s patent number 11,826,327.
Following the recent crash, Liquidia shares are trading about 70% below their recent high.